Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913313 | 0.79 | TDP1 (0.44) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL12958889 | 0.79 | TSHR (0.42) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL410825 | 0.79 | TSHR (0.50) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL10389565 | 0.77 | TSHR (0.40) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL12405369 | 0.76 | POLB (0.40) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL4402992 | 0.76 | MGAM (0.46) | TP53TDP1TSHRPPARDCYP3A4 | |
| SCHEMBL18052649 | 0.76 | TSHR (0.39) | TP53TDP1TSHRPPARDCA12 | |
| SCHEMBL18309148 | 0.75 | — | — | |
| SCHEMBL575282 | 0.75 | — | — | |
| SCHEMBL10490232 | 0.74 | TSHR (0.42) | TP53TDP1TSHRPPARDCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | US | disclosed |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9409908-B2 | Dihydropyridone p1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409908-B2 | Dihydropyridone p1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9376444-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376444-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150166550-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-20150166550-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-20140038969-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-06 | — | — | US | disclosed |
| US-20140038969-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | TFPI, TFPI2, F2 | TP53 4431/4885TDP1 3093/4885TSHR 2906/4885 |
| US-20140038969-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | TP53 4053/4885TDP1 682/4885TSHR 3407/4885 |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | TFPI, TFPI2, F2 | TP53 4431/4885TDP1 3093/4885TSHR 2906/4885 |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | TFPI, TFPI2, F11 | TP53 4677/4885TDP1 2747/4885TSHR 2634/4885 |
| US-20150166550-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | TP53 4053/4885TDP1 682/4885TSHR 3407/4885 |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | TFPI, TFPI2, F2 | TP53 4644/4885TDP1 1817/4885TSHR 3245/4885 |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | TP53 4020/4885TDP1 767/4885TSHR 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.